ID   VU-SCC-096
AC   CVCL_JL63
SY   93VU096Ta; 93VU096aT
DR   cancercelllines; CVCL_JL63
DR   Wikidata; Q54993381
RX   PubMed=8824719;
RX   PubMed=9139877;
RX   PubMed=23613873;
RX   PubMed=31541927;
CC   Doubling time: 41 +- 3 hours (PubMed=9139877).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (PubMed=23613873; PubMed=31541927).
CC   Omics: Genome sequenced (low read coverage).
CC   Derived from site: In situ; Oral cavity, retromolar trigone; UBERON=UBERON_0012376.
DI   NCIt; C8172; Retromolar trigone squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   42Y
CA   Cancer cell line
DT   Created: 15-05-17; Last updated: 05-10-23; Version: 11
//
RX   PubMed=8824719; DOI=10.1002/(SICI)1098-2264(199601)15:1<1::AID-GCC1>3.0.CO;2-8;
RA   Hermsen M.A.J.A., Joenje H., Arwert F., Welters M.J.P., Braakhuis B.J.M.,
RA   Bagnay M., Westerveld A., Slater R.M.;
RT   "Centromeric breakage as a major cause of cytogenetic abnormalities in
RT   oral squamous cell carcinoma.";
RL   Genes Chromosomes Cancer 15:1-9(1996).
//
RX   PubMed=9139877; DOI=10.1002/(SICI)1097-0215(19970502)71:3<410::AID-IJC18>3.0.CO;2-J;
RA   Welters M.J.P., Fichtinger-Schepman A.M.J., Baan R.A., Hermsen M.A.J.A.,
RA   van der Vijgh W.J.F., Cloos J., Braakhuis B.J.M.;
RT   "Relationship between the parameters cellular differentiation,
RT   doubling time and platinum accumulation and cisplatin sensitivity in a
RT   panel of head and neck cancer cell lines.";
RL   Int. J. Cancer 71:410-415(1997).
//
RX   PubMed=23613873; DOI=10.1371/journal.pone.0061555; PMCID=PMC3629194;
RA   Martens-de Kemp S.R., Dalm S.U., Wijnolts F.M.J., Brink A.,
RA   Honeywell R.J., Peters G.J., Braakhuis B.J.M., Brakenhoff R.H.;
RT   "DNA-bound platinum is the major determinant of cisplatin sensitivity
RT   in head and neck squamous carcinoma cells.";
RL   PLoS ONE 8:E61555-E61555(2013).
//
RX   PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004; PMCID=PMC7372097;
RA   van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I.,
RA   Leemans C.R., Wolthuis R.M.F., Brakenhoff R.H.;
RT   "Characterization of a head and neck cancer-derived cell line panel
RT   confirms the distinct TP53-proficient copy number-silent subclass.";
RL   Oral Oncol. 98:53-61(2019).
//